Functional Dyspepsia Symptom Diary (FDSD)
OVERVIEW
The purpose of the Functional Dyspepsia Symptom Diary (FDSD) is to assess the severity of functional dyspepsia (FD) symptoms via patient self-report, and it is intended for administration as a daily diary. The FDSD was developed to address the lack of symptom-focused PRO measures designed for use among people diagnosed with FD and meeting FDA recommendations for PRO measure development as established in FDA’s guidance for industry titled Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims (US Food and Drug Administration 2009). The FDSD is intended for inclusion in clinical research to support the assessment of FD treatment benefit.
The FDSD has not been qualified by the U.S. Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research (CDER). To support its use, the Patient-Centered Evidence (PCE) Consortium will make available the following evidence compiled as part of the qualification effort undertaken by the Functional Dyspepsia Working Group when the measure is licensed to help support a sponsor’s use of the measure and development of an evidence dossier.
-
Qualitative Research Summary Report
-
Qualification Plan which includes the following:
-
Pilot Study Protocol
-
Quantitative Analysis Plan
-
-
Qualification Briefing Package
-
Measure name: Functional Dyspepsia Symptom Diary (FDSD)
-
Number of items: 8
-
Target patient population: Adults (age 18 years and older) diagnosed with functional dyspepsia
-
Concept of interest: functional dyspepsia symptom severity
-
Recall period: Past 24 hours
-
Response scale: 11-point (0-10) numeric rating scale (NRS)
-
Mode of data collection: Electronic administration is recommended for the FDSD. Previous studies were conducted using a handheld electronic diary device (e.g., smartphone).
USER MANUAL
Available with license
Available translations of the FDSD can be obtained when licensing the measure(s). To ensure standardized translations, users are not permitted to translate the FDSD without prior, written permission from the PCE Consortium. Please contact us for more details. Please contact us for more details.
PREFERRED TRANSLATION VENDOR FOR NSCLC-SAQ
FACITtrans
LICENSING
Licensing fees are assessed on a per trial/per measure basis for commercial use.
-
PCE Consortium Member Firms:
-
First Language $1000 USD
-
Each Additional/Available Language $500 USD
-
-
Non-Member Organizations
-
First Language $4000 USD
-
Each Additional/Available Language $2000 USD
-
Non-commercial use is assessed on a case-by-case basis for appropriateness and applicability.
To license the FDSD, please complete the licensing form. All of the information provided in the form will be kept strictly confidential. For questions about the measure, please contact us.
Functional Dyspepsia Symptom Diary (FDSD) Version 1.0. © 2017 CRITICAL PATH INSTITUTE. ALL RIGHTS RESERVED.
PUBLICATIONS
Taylor F, Reasner DS, Carson RT, Deal LS, Foley C, Iovin R, Lundy JJ, Pompilus F, Shields AL, Silberg DG. Development of a symptom-based patient-reported outcome instrument for functional dyspepsia: a preliminary conceptual model and an evaluation of the adequacy of existing instruments. The Patient - Patient-Centered Outcomes Research. 2016;9:409-418. (https://link.springer.com/article/10.1007%2Fs40271-016-0164-1)
